INNOVATION AND PASSION

Our employees and our work culture make the difference

MEET OUR TEAM

Our entire team is committed to improving the quality of life of patients. We find sense in our work by appreciating how our efforts successfully help patients.

THE THREE FOUNDERS

DEMECAN was founded in 2017 by physician Dr. Adrian Fischer (left), lawyer Dr. Constantin von der Groeben (right) and economist Dr. Cornelius Maurer (center). With their combined expertise, they are working on advancing medical cannabis in Germany. They use their different skills and knowledge effectively to successfully master the challenging business model as wholesalers and producers.

Management

Dr. Adrian G. Fischer

Managing Director Co-Founder
Licensed Physician

Dr. Constantin von der Groeben

Managing Director Co-Founder
Lawyer

Jörg Sellmann

Managing Director
MBA

Dr. Philipp Goebel

Managing Director
Marketing and Sales expert

Europe is changing with us

Besides Germany, many other European countries have also recognized the potential of medical cannabis for patient health. In all countries with medical access to cannabis, patient numbers have increased significantly in recent years. We want to support European countries, which have decided to provide access to modern cannabis therapies to their citizens and patients.

Medical-Scientific Advisory Board

DEMECAN is advised by a team of nationally and internationally recognized experts from science, medicine and pharmacy. With years of practical experience and high level of commitment to the establishment of cannabinoid-therapy, our experts provide strategic and medical-scientific advice and support DEMECAN by improving patient care.

Prof. Dr. Kirsten Müller-Vahl

Prof. Dr. Kirsten Müller-Vahl is a professor and senior physician at the Department of Psychiatry, Social Psychiatry and Psychotherapy at the Hannover Medical School (MHH, Germany). Her scientific focus is on Tourette’s syndrome and other tic disorders. Prof. Müller-Vahl has been committed to cannabis as medicine since the late 1990s as a founding member and chair of the International Working Group on Cannabis as Medicine.

Prof. Dr. Dr. Joachim Nadstawek

Prof. Dr. Dr. Joachim Nadstawek is a specialist in anesthesiology at the Schmerzzentrum Jankerklinik in Bonn (Germany). He is also Chairman of the Professional Association of Physicians and Psychological Psychotherapists in Pain and Palliative Medicine in Germany e.V. (BVSD). Prof. Nadstawek has been committed to improving patient care, especially for chronic pain patients, for many years.

Prof. Dr. Thomas Herdegen

Prof. Dr. med. Thomas Herdegen is deputy director of the Institute for Experimental and Clinical Pharmacology at Kiel University with a research focus on neuropharmacology and pain pharmacology. He has long been an advocate for the establishment of cannabis as a therapeutic option, collaborates on clinical trials with cannabis, and is an editor for a variety of different media outlets.

Dr. Marc Seibolt

Dr. Marc Seibolt is a specialist in anaesthesiology and special pain therapy, emergency medicine and addiction medicine as well as head physician of the Algesiologikum in Munich. With numerous years of extensive practical experience and publications, Dr. Seibolt has been making an immense contribution to the education and establishment of cannabinoids as a therapeutic option for many years.

Dr. Dennis Stracke

Dr. Dennis Stracke is one of Germany’s most renowned pharmacists and experts with regards to medical cannabis. As a founding member and vice chairman of the board of the Verband der Cannabis versorgenden Apotheken e.V. (VCA), he is committed to the sustainable improvement of patient care and support. In addition, as a licensed pharmacist, Dr. Stracke heads the neurology and rare diseases department at MediosApotheke.

Working at DEMECAN

Do you want to complement our team? We offer great opportunities to become a part of our team at three different locations in Germany.

Investors

Would you like to invest in DEMECAN or do you have any questions about investment opportunities? We are looking forward to receiving your message!